174 related articles for article (PubMed ID: 37974198)
1. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract][Full Text] [Related]
2. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
[TBL] [Abstract][Full Text] [Related]
3. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
[TBL] [Abstract][Full Text] [Related]
4. Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin.
Lee YT; Ayoub A; Park SH; Sha L; Xu J; Mao F; Zheng W; Zhang Y; Cho US; Dou Y
Nat Commun; 2021 May; 12(1):2953. PubMed ID: 34012049
[TBL] [Abstract][Full Text] [Related]
5. ASH2L, a COMPASS core subunit, is involved in the cell invasion and migration of triple-negative breast cancer cells through the epigenetic control of histone H3 lysine 4 methylation.
Batbayar G; Ishimura A; Lyu H; Wanna-Udom S; Meguro-Horike M; Terashima M; Horike SI; Takino T; Suzuki T
Biochem Biophys Res Commun; 2023 Aug; 669():19-29. PubMed ID: 37262949
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor Ap2delta associates with Ash2l and ALR, a trithorax family histone methyltransferase, to activate Hoxc8 transcription.
Tan CC; Sindhu KV; Li S; Nishio H; Stoller JZ; Oishi K; Puttreddy S; Lee TJ; Epstein JA; Walsh MJ; Gelb BD
Proc Natl Acad Sci U S A; 2008 May; 105(21):7472-7. PubMed ID: 18495928
[TBL] [Abstract][Full Text] [Related]
7. Fgfr3 is a transcriptional target of Ap2delta and Ash2l-containing histone methyltransferase complexes.
Tan CC; Walsh MJ; Gelb BD
PLoS One; 2009 Dec; 4(12):e8535. PubMed ID: 20046871
[TBL] [Abstract][Full Text] [Related]
8. Generation of an arrayed CRISPR-Cas9 library targeting epigenetic regulators: from high-content screens to in vivo assays.
Henser-Brownhill T; Monserrat J; Scaffidi P
Epigenetics; 2017; 12(12):1065-1075. PubMed ID: 29327641
[TBL] [Abstract][Full Text] [Related]
9. ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Zeng K; Wu Y; Wang C; Wang S; Sun H; Zou R; Sun G; Song H; Liu W; Sun N; Wei S; Liu W; Su Y; Zhou T; Zhang Y; Zhao Y
Cancer Sci; 2020 Jun; 111(6):2062-2077. PubMed ID: 32279431
[TBL] [Abstract][Full Text] [Related]
10. Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes.
Butler JS; Zurita-Lopez CI; Clarke SG; Bedford MT; Dent SY
J Biol Chem; 2011 Apr; 286(14):12234-44. PubMed ID: 21285357
[TBL] [Abstract][Full Text] [Related]
11. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.
Yedier-Bayram O; Gokbayrak B; Kayabolen A; Aksu AC; Cavga AD; Cingöz A; Kala EY; Karabiyik G; Günsay R; Esin B; Morova T; Uyulur F; Syed H; Philpott M; Cribbs AP; Kung SHY; Lack NA; Onder TT; Bagci-Onder T
Cell Death Dis; 2022 Aug; 13(8):710. PubMed ID: 35973998
[TBL] [Abstract][Full Text] [Related]
12. Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma.
Liu X; Cao Z; Wang W; Zou C; Wang Y; Pan L; Jia B; Zhang K; Zhang W; Li W; Hao Q; Zhang Y; Zhang W; Xue X; Lin W; Li M; Gu J
ACS Nano; 2023 Sep; 17(17):16432-16447. PubMed ID: 37646615
[TBL] [Abstract][Full Text] [Related]
13. Expression specificity and compensation effect of Ash2l-1/Ash2l-2 in mouse embryonic stem cells.
Xie J; Fan C; Zhang JL; Zhang SQ
Yi Chuan; 2018 Mar; 40(3):237-249. PubMed ID: 29576547
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the trithorax group protein ASH2L reveals a forkhead-like DNA binding domain.
Sarvan S; Avdic V; Tremblay V; Chaturvedi CP; Zhang P; Lanouette S; Blais A; Brunzelle JS; Brand M; Couture JF
Nat Struct Mol Biol; 2011 Jun; 18(7):857-9. PubMed ID: 21642971
[TBL] [Abstract][Full Text] [Related]
15. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
16. Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
Butler JS; Qiu YH; Zhang N; Yoo SY; Coombes KR; Dent SY; Kornblau SM
Leuk Lymphoma; 2017 May; 58(5):1207-1218. PubMed ID: 28185526
[TBL] [Abstract][Full Text] [Related]
17. ASH2L Controls Ureteric Bud Morphogenesis through the Regulation of RET/GFRA1 Signaling Activity in a Mouse Model.
Zhao Z; Dai X; Jiang G; Lin F
J Am Soc Nephrol; 2023 Jun; 34(6):988-1002. PubMed ID: 36758123
[TBL] [Abstract][Full Text] [Related]
18. Ash2l interacts with Tbx1 and is required during early embryogenesis.
Stoller JZ; Huang L; Tan CC; Huang F; Zhou DD; Yang J; Gelb BD; Epstein JA
Exp Biol Med (Maywood); 2010 May; 235(5):569-76. PubMed ID: 20463296
[TBL] [Abstract][Full Text] [Related]
19. The Ash2l SDI Domain Is Required to Maintain the Stability and Binding of DPY30.
Ma M; Zhou J; Ma Z; Chen H; Li L; Hou L; Yin B; Qiang B; Shu P; Peng X
Cells; 2022 Apr; 11(9):. PubMed ID: 35563756
[TBL] [Abstract][Full Text] [Related]
20. The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation.
Nayak A; Viale-Bouroncle S; Morsczeck C; Muller S
Mol Cell; 2014 Jul; 55(1):47-58. PubMed ID: 24930734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
